Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 safety and efficacy study of rAAV1-CB-hAAT in alpha-1 antitrypsin deficiency
2009-014286-20Phase 2Completed
- Sponsor
- Applied Genetic Technologies Corporation
- Start
- May 2010
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rAAV1-CBA-hAAT in alpha-1 antitrypsin deficiency (AATD), sponsored by Applied Genetic Technologies Corporation. Primary endpoint: Safety outcomes. Started May 2010; status: completed.
02
Drugs
rAAV1-CBA-hAAT
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on 2009-014286-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014286-20.